ACADIA Pharmaceuticals Inc (NAS:ACAD)
$ 16.95 -0.42 (-2.42%) Market Cap: 2.89 Bil Enterprise Value: 2.37 Bil PE Ratio: 22.27 PB Ratio: 5.01 GF Score: 75/100

ACADIA Pharmaceuticals Inc at Bank of America Healthcare Conference Transcript

May 10, 2022 / 10:20PM GMT
Release Date Price: $16.84 (+2.81%)
Tazeen Ahmad
BofA Securities, Research Division - MD in Equity Research & Research Analyst

Everybody, good afternoon. So thanks for joining us again at the Bank of America Healthcare Conference. I am Tazeen Ahmad. I am one of the SMID biotech analysts here at the bank. It's a pleasure for us to have our next presenting company with us, ACADIA Pharmaceuticals. Sitting next to me are Steve and Mark. I'll let you guys introduce yourselves, and then maybe, Steve, you can give us a quick overview of the company, and then we can do a little bit more specific Q&A after that, if that works for you.

Stephen R. Davis
ACADIA Pharmaceuticals Inc. - CEO & Director

Yes, it sounds great. So I'm Steve Davis, I'm the CEO of ACADIA.

Mark C. Schneyer
ACADIA Pharmaceuticals Inc. - Executive VP & CFO

And I'm Mark Schneyer, I'm the CFO of ACADIA.

Stephen R. Davis
ACADIA Pharmaceuticals Inc. - CEO & Director

Great. So thanks very much for having us, Tazeen. Thanks to

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot